The Global Solid Tumor Summit will unite cancer researchers, oncologists, data specialists and cancer survivors. Here’s a preview of what you can expect:
Educational presentations showcasing the latest solid tumor research
How advances in technology, such as digital PCR and next-generation sequencing, respectively, contribute to give greater speed and accurate test results
Panel discussions, including a patient’s perspective of the treatment journey
Case studies on biomarker testing in lung and colorectal cancer
How the latest companion diagnostics are influencing biomarker testing
The chance to pose questions to the speakers and panels
The Global Solid Tumor Summit is CME and CPD-accredited*
By participating in the summit, you will earn CME credits and CPD certification (validated shortly after the event). That's two more good reasons to join us on April 25 and 26.
A considerable global burden
Even in 2023, the global burden of cancer is enormous. With almost 20 million cases diagnosed and 10 million deaths in 2020 (1), it is the second leading cause of death worldwide (2). Solid tumors make up ~90% of those cancers (1).
Sadik H, et al. Impact of clinical practice gaps on the implementation of personalized medicine in advanced non-small-cell lung cancer. JCO Precis Oncol. 2022;6:e2200246.
Integrating biomarker testing into cancer care
One of the most significant challenges in cancer treatment is access to timely biomarker testing, which in turn facilitates access to targeted treatments. This challenge is evidenced both at the laboratory level and for clinicians, with new biomarkers and technologies to adapt to, changing clinical guidelines and turnaround time for test results all contributing to the issue.
The scale of the problem is exemplified in a recent study on access to personalized medicine in advanced non-small cell lung cancer (NSCLC) (3). For every 1000 patients in the cohort, the study found that 497 (49.7%) did not benefit from precision medicine, partly due to factors associated with getting biomarker test results (3).
In pursuit of a life for every patient
We all have the same goal – to contribute to improving the lives of every patient with cancer. So, what can be done to start addressing these challenges? On April 25 and 26, we’re bringing together global oncology experts for a two-day live event to investigate and discuss just that.
Join us to address the current challenges, share the latest information in diagnostic testing and discuss the latest technological advances. Together, we’ll strive to support and advance cancer research and diagnostics, and in turn, help expand the horizons of cancer treatment.
Are you ready to join us? Register now
Fill out the registration form to save your spot and receive regular event updates.
* Continuing Medical Education
QIAGEN is accredited by the American Association of Continuing Medical Education® to provide continuing medical education for physicians. The Accreditation Review Committee designates this educational activity for a maximum of 9.75 hours category I credits in the Association’s Credit Designation. Each physician must claim only those credits that he/she actually spent in the educational activity.
It is the policy of the American Association of Continuing Medical Education® to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational programs. All faculty participating in continuing medical education activities sponsored by QIAGEN are required to disclose to the program audience any real or apparent conflict of interest related to the content of their presentations. All faculty are also required to disclose any discussions of unlabeled/unapproved uses of drugs or devices.